Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04972721 · ClinicalTrials.gov registry record
SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial
A clinical trial of Obesity and Overweight, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 3,439
- Enrollment target
- 20
- Study locations
NCT04972721: Completed study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
NCT04972721 is a study of Obesity and Overweight that has completed, run by Novo Nordisk A/S. The registered enrollment target is 3,439 participants, above the 816-participant average among 1,053 other Obesity trials with a reported enrollment target (321% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04972721, a study of Obesity and Overweight, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 3,439 participants
- Enrollment target
- 20
- Study locations
Study Summary
Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking. When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take part in the SELECT-LIFE study. Participants will not get any specific treatment or medicine as part of the SELECT-LIFE study, and participants will be treated as participants normally would by their own doctor. The SELECT-LIFE study will last for up to 10 years after SELECT trial ends, and participants will be asked to fill in a questionnaire about their health every 6 months.
Primary Outcome
Measured in months
Conditions Studied
Interventions
- OTHER No treatment given
Study Locations (20)
São Paulo
- Instituto de Pesquisa Clínica de Campinas - Campinas
- CIP Centro Integrado de Pesquisas do Hospital de Base - São José do Rio Preto
- CPQuali Pesquisa Clínica Ltda - São Paulo
- CPCLIN - Centro de Pesquisas Clínicas - São Paulo
- Instituto Dante Pazzanese de Cardiologia - São Paulo
- Departamento de Gastroenterologia - HCFMUSP - São Paulo
- Instituto do Coração - HCFMUSP - São Paulo
- Master Centre for Brazil - Säo Paulo
Other
- Master Centre for Algeria - Algiers
- Master Centre for Argentina - Prov. de Buenos Aires
- Instituto Brasil de Pesquisa Clinica - Rio de Janeiro
New Jersey
- Master Centre for USA - Plainsboro
New South Wales
- Master Centre for Australia - North Sydney
Estado de Bahia
- Cárdio Pulmonar da Bahia - Salvador
Federal District
- Hospital do Coração do Brasil - Brasília
Minas Gerais
- Eurolatino Medical Research Center - Uberlândia
Paraná
- Núcleo de Pesquisa Clínica S/S - Curitiba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,439 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2025-08-25 |
What the finished NCT04972721 record still lists
NCT04972721 is an observational study that tracks outcomes without assigning an intervention. Its 3,439 participants enrollment target places it among the larger protocols in the corpus, above the 816-participant average among 1,053 other Obesity trials with a reported enrollment target (321% higher).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which No treatment given is the first listed.
NCT04972721 names 20 study sites across 11 states, led by São Paulo, Other, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04972721 about?
NCT04972721 is a clinical study titled "SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial". Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial incl...
What is the current status of trial NCT04972721?
This trial is currently completed. The enrollment target is 3,439 participants. The study started on 2023-09-01. Estimated completion is 2025-08-25.
What conditions does trial NCT04972721 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT04972721?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT04972721?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04972721 being conducted?
This trial has 20 study locations across New Jersey, New South Wales, Estado de Bahia, Federal District, Minas Gerais. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04972721's enrollment target sits among peer trials
3,439 30th of 1053 higher than 1,024 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI